

CELL THERAPEUTICS INC
Form NT 10-Q
November 09, 2005
(Check One):

SEC File Number:

001-12465

Form 10-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Form 20-F

Washington, D.C. 20549

Form 11-K

Form 10-Q

FORM 12b-25

Form N-SAR

Form N-CSR

NOTIFICATION OF LATE FILING

For Period Ended: **September 30, 2005**

Transition Report on Form 10-K

Transition Report on Form 20-F

Transition Report on Form 11-K

Transition Report on Form 10-Q

Transition Report on Form N-SAR

For the Transition Period Ended: _____

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

CELL THERAPEUTICS, INC.

Full Name of Registrant

Former Name if Applicable

501 Elliott Avenue West, Suite 400

Address of Principal Executive Office (Street and number)

Seattle, WA 98119

City, State and Zip Code

PART II - RULES 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12-b-25(b), the following should be completed. (Check box if appropriate.):

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- X (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

We are unable to file our Form 10-Q Quarterly Report for the period ended September 30, 2005 as Stonefield Josephson, Inc., our independent accountants who were appointed on October 14, 2005, have not yet completed their review of our unaudited financial statements. It is anticipated that our Form 10-Q Quarterly Report, along with our unaudited financial statements, will be filed on or before the 5th calendar day following the prescribed filing date of November 9, 2005.

PART IV- OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification:

Louis A. Bianco

206

282-7100

(Name)

(Area Code)

(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s): Yes No
-

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?: Yes No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

CELL THERAPEUTICS, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 9, 2005

By: /s/ Louis A. Bianco

Louis A. Bianco

Executive Vice President

Finance and Administration

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).